In vivo antinociception of potent mu opioid agonist tetrapeptide analogues and comparison with a compact opioid agonist - neurokinin 1 receptor antagonist chimera

BACKGROUND: An important limiting factor in the development of centrally acting pharmaceuticals is the blood-brain barrier (BBB). Transport of therapeutic peptides through this highly protective physiological barrier remains a challenge for peptide drug delivery into the central nervous system (CNS)...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Guillemyn, Karel, Kleczkowska, Patrycja, Novoa, Alexandre, Vandormael, Bart, Van den Eynde, Isabelle, Kosson, Piotr, Asim, Muhammad Faheem, Schiller, Peter W, Spetea, Mariana, Lipkowski, Andrzej W, Tourwé, Dirk, Ballet, Steven
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2012
Предметы:
Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3284447/
https://ncbi.nlm.nih.gov/pubmed/22289619
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-6606-5-4
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы